Business

Gilead plans to produce two million remdesivir courses by 2020 end

Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.

migrator

Bengaluru

Remdesivir, which is currently administered intravenously, is the first drug to show effectiveness against COVID-19 in human trials, and its emergency use has been permitted by several countries including the United States.

An inhaled formulation would be given through a nebulizer, which could potentially allow for easier use outside hospitals, Gilead said.

Gilead has set up licensing agreements with nine generic drugmakers to ramp up supply of remdesivir, Chief Executive Officer Daniel O'Day said in a statement. 

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Also Read

Draft roll released; how to find your details, what to do if name not found

SIR: 1 in 3 voters axed from Chennai's draft electoral roll

EPS condemns detention, accuses DMK government of betrayal

Over 2.37L flagged as ‘no mapping’ in Chennai

DMK, allies plan state-wide stir against Centre, AIADMK over G Ram G Bill